Show simple item record

dc.contributor.authorCOvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uken_US
dc.contributor.authorCOvid-19 Multi-omics Blood ATlas (COMBAT) Consortiumen_US
dc.date.accessioned2022-11-15T13:25:42Z
dc.date.available2022-01-17en_US
dc.date.issued2022-03-03en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/82435
dc.description.abstractTreatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19.en_US
dc.format.extent916 - 938.e58en_US
dc.languageengen_US
dc.relation.ispartofCellen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectblooden_US
dc.subjectcoronavirusen_US
dc.subjectepigeneticsen_US
dc.subjectimmuneen_US
dc.subjectmulti-omicsen_US
dc.subjectpersonalized medicineen_US
dc.subjectproteomicsen_US
dc.subjecttranscriptomicsen_US
dc.subjectAdulten_US
dc.subjectBiomarkersen_US
dc.subjectBlood Proteinsen_US
dc.subjectCOVID-19en_US
dc.subjectCell Cycle Proteinsen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectInfluenza, Humanen_US
dc.subjectLymphocytesen_US
dc.subjectMachine Learningen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectMitogen-Activated Protein Kinase 14en_US
dc.subjectMonocytesen_US
dc.subjectPrincipal Component Analysisen_US
dc.subjectProteomeen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSepsisen_US
dc.subjectSeverity of Illness Indexen_US
dc.subjectTranscription Factor AP-1en_US
dc.titleA blood atlas of COVID-19 defines hallmarks of disease severity and specificity.en_US
dc.typeArticle
dc.identifier.doi10.1016/j.cell.2022.01.012en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35216673en_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume185en_US
dcterms.dateAccepted2022-01-17en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States